Startup profile for Cardiogram: latest funding, latest known valuation, total disclosed funding, investors, status, sources, and why the company is interesting. Part of the Venture Capital Tracker startup directory.

Startup profile · funding coverage

Cardiogram funding, valuation and investors

Apple Watch and wearable analytics for heart health and arrhythmia detection.

Keep track of Cardiogram

Save this profile to your VCT watchlist for a quick return.

View watchlist

Funding, valuation & investors

Answer-first snapshot

Latest funding

Seed

$2M · October 2016

Latest known valuation

Not publicly disclosed

Total disclosed equity funding

$2M

Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.

Current status

acquired

acquired

Investors in latest funding

Lead: Andreessen Horowitz

Sources: latest funding Last verified: 2026-07-25

Overview

Cardiogram analyzed Apple Watch and wearable heart-rate data using its DeepHeart neural network for arrhythmia and cardiovascular risk signals. a16z Bio led a $2M seed in 2016. ilumivu acquired Cardiogram in October 2021, continuing cardiovascular monitoring capabilities.

Why Cardiogram is interesting

Cardiogram's DeepHeart neural net turned consumer wearables into cardio screening tools — a16z Bio led seed before ilumivu acquired it in 2021.

Product & use cases

Wearable analytics app using DeepHeart ML on Apple Watch data for heart health and arrhythmia screening.

  • Consumer heart rhythm monitoring via Apple Watch
  • Atrial fibrillation detection research workflows
  • Wearable-derived cardio risk signals

Key facts

  • Acquired by ilumivu (Oct 2021): cardiovascular monitoring app (PR Newswire)
  • Seed (Oct 2016): $2M led by a16z Bio; Homebrew angels participated (TechCrunch)
  • Co-investors: no additional institutional investors disclosed in public sources reviewed 2026-07-24
  • Source: https://techcrunch.com/2016/10/20/cardiogram-raises-2-million-to-predict-heart-health-issues-using-wearbles/

Funding history (newest first)

Investors in our directory

Funds linked from Cardiogram's profile — open a fund page for stage focus and related deal articles.

Competitive landscape

Edge: Cardiogram differentiates through focused product scope and a16z-backed GTM in its category — see competitors for tradeoffs vs. incumbents.

Cardiogram operates in a competitive category where incumbents have distribution but startups win on workflow fit. See named competitors for honest better/worse notes; we do not invent market share.

  • Apple Health incumbent

    Native AFib notifications; Cardiogram added research-grade analytics.

  • Fitbit/Google adjacent

    Wearable ecosystem competitor set.

Notable stories

  • Acquired by ilumivu (Oct 2021): cardiovascular monitoring app (PR Newswire)
  • Seed (Oct 2016): $2M led by a16z Bio; Homebrew angels participated (TechCrunch)

Industries

Healthtech AI & Machine Learning Consumer

Related funding articles

Venture Capital Tracker pieces that cover Cardiogram's financing or category context.

FAQs about Cardiogram

Practical answers founders, operators, and investors typically search for.

Wearable analytics app using DeepHeart ML on Apple Watch data for heart health and arrhythmia screening.
Andreessen Horowitz (/fund/andreessen-horowitz) among disclosed investors. See fundraising rounds and investors[] for co-investors in our directory.
We track a16z-backed companies strategically relevant for founders mapping competitors and investors following active theses.
Stage: acquired; status: acquired.
See fundraisingRounds — amounts included only when verified in press or company announcements.
See competitors and competitiveAnalysis sections for named alternatives.
Profitability not publicly disclosed unless noted in highlights. Public companies: check SEC filings.
Tagged: healthtech, ai-ml, consumer.

By Venture Capital Tracker

Last updated:

Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.